Please assess the completion status of the following clinical trial:

Trial Title: EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years or at full age as required by local regulation~* Evidence of chronic kidney disease at risk of kidney disease progression defined by at least 3 months before and at the time of Screening Visit~  * CKD-EPI eGFR ≥20 to \<45 mL/min/1.73m² or~ * CKD-EPI eGFR ≥45 to \<90 mL/min/1.73m² with urinary albumin:creatinine ratio ≥200 mg/g (or protein:creatinine ratio ≥300 mg/g);~* Clinically appropriate doses of single agent RAS-inhibition with either ACEi or ARB unless such treatment is either not tolerated or not indicated~* A local Investigator judges that the participant neither requires empagliflozin (or any other SGLT-2 or SGLT-1/2 inhibitor), nor that such treatment is inappropriate;~Key Exclusion Criteria:~* Currently receiving SGLT-2 or SGLT-1/2 inhibitor~* Diabetes mellitus type 2 and prior atherosclerotic cardiovascular diseasee with an eGFR \>60 mL/min/1.73m2 at Screening~* Receiving combined ACEi and ARBf treatment~* Maintenance dialysis, functioning kidney transplant, or scheduled living donor transplant~* Polycystic kidney disease~* Previous or scheduled bariatric surgery~* Ketoacidosis in the past 5 years~* Symptomatic hypotensiond, or systolic blood pressure \<90 or \>180 mmHg at Screening~* ALT or AST \>3x ULN at Screening~* Hypersensitivity to empagliflozin or other SGLT-2 inhibitor~* Any intravenous immunosuppression therapy in last 3 months; or anyone currently on \>45 mg prednisolone (or equivalent)~* Use of an investigational medicinal product in the 30 days prior to Screening visit~* Known to be poorly compliant with clinic visits or prescribed medication~* Medical history that might limit the individual's ability to take trial treatments for the duration of the study (e.g. severe respiratory disease; history of cancer or evidence of spread within last 4 years, other than non-melanoma skin cancer; or recent history of alcohol or substance misuse)~* Current pregnancy, lactation or women of childbearing potential (WOCBP), unless using highly-effective contraception~* Type 1 diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Empagliflozin 10 mg (Type: EXPERIMENTAL): Patients with evidence of chronic kidney disease (CKD) at risk of kidney disease progression, with or without diagnosed diabetes mellitus administered orally once daily 10 milligram (mg) film-coated tablets of empagliflozin.
- Placebo (Type: PLACEBO_COMPARATOR): Patients with evidence of chronic kidney disease (CKD) at risk of kidney disease progression, with or without diagnosed diabetes mellitus administered orally once daily film-coated tablets of placebo to match empagliflozin.

Based on this trial design, predict the completion outcome and termination type (if applicable).